Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung

J Clin Oncol. 2011 Aug 10;29(23):e675-7. doi: 10.1200/JCO.2011.35.0439. Epub 2011 Jun 20.

Authors

Motoko Tachihara¹, Kenichi Misa, Manabu Uematsu, Hiroyuki Minemura, Yutaka Katsuura, Takashi Ishida, Mitsuru Munakata

Affiliation

¹ Saiseikai Fukushima General Hospital, Fukushima, Japan.

PMID: 21690480
DOI: 10.1200/JCO.2011.35.0439

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / complications
Adenocarcinoma / drug therapy*
Adenocarcinoma / pathology
Aged
Anti-Inflammatory Agents / therapeutic use
Antineoplastic Agents / therapeutic use*
Ascites / drug therapy
Ascites / etiology
Ascites / pathology*
Erlotinib Hydrochloride
Humans
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Pleural Effusion, Malignant / drug therapy
Pleural Effusion, Malignant / etiology
Pleural Effusion, Malignant / pathology*
Prednisolone / therapeutic use
Quinazolines / therapeutic use*

Substances

Anti-Inflammatory Agents
Antineoplastic Agents
Quinazolines
Prednisolone
Erlotinib Hydrochloride